Shanrong Competitors

Pink Sheets . USA . 
Stock . Shanrong Biotechnology Corp
SRBT Stock  USD 0.1  0.00  0.00%   
Shanrong Biotechnology competes with Xunlei, WK Kellogg, Capital Clean, Ingredion Incorporated, and Global E; as well as few others. The company conducts business under Financial Services sector and is part of Shell Companies industry. Analyzing Shanrong Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Shanrong Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Shanrong Biotechnology Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Shanrong Biotechnology competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.109.88
Details
Intrinsic
Valuation
LowRealHigh
0.000.099.87
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Shanrong Biotechnology. Your research has to be compared to or analyzed against Shanrong Biotechnology's peers to derive any actionable benefits. When done correctly, Shanrong Biotechnology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Shanrong Biotechnology.

Shanrong Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Shanrong Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Shanrong and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Shanrong Biotechnology does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GLBE
+ 0.69
KLG
VLGEA
+ 0.67
INGR
INGR
+ 0.55
KLG
VLGEA
+ 0.54
GLBE
VLGEA
+ 0.49
KLG
COE
+ 0.49
GLBE
  
High negative correlations   
IPG
- 0.6
COE
GLBE
- 0.51
CCEC
CCEC
- 0.47
KLG
INGR
- 0.4
CCEC
IPG
- 0.38
GLBE
VLGEA
- 0.38
CCEC

Risk-Adjusted Indicators

There is a big difference between Shanrong Pink Sheet performing well and Shanrong Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Shanrong Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Shanrong Biotechnology Competitive Analysis

The better you understand Shanrong Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Shanrong Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Shanrong Biotechnology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SRBT XNET KLG CCEC INGR GLBE VLGEA COE IPG
 0.00 
 0.1 
Shanrong
 0.47 
 2.10 
Xunlei
 6.74 
 16.32 
KLG
 1.41 
 18.24 
Capital
 0.60 
 133.51 
Ingredion
 0.44 
 52.78 
Global
 7.01 
 32.51 
Village
 0.99 
 20.00 
51Talk
 0.61 
 27.53 
Interpublic
Market Volatility
(90 Days Market Risk)
Out of control
Moderately volatile
Not too volatile
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Insignificant
Weak
Weak
Weak
Solid
Insignificant
Good
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Very Low
Below Average
Very Low
Low
Low
Very Low
Very Low
Very Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Sell
Hold
Strong Buy
Buy
Strong Buy
Strong Sell
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Hold
Strong Hold
Strong Buy
Strong Hold
Strong Sell
Strong Hold
Current Ratio
N/A
2.71
N/A
N/A
1.72
2.76
1.5
1.76
1.04
Net Asset
24.78 K
468.69 M
1.89 B
3.14 B
7.64 B
1.2 B
981.66 M
31.16 M
19.27 B
Profit Margin
N/A
0.0453
0.025
0.25
0.0905
-0.17
0.0226
-0.41
0.0865
EBITDA
N/A
25.99 M
221 M
237.16 M
1.17 B
47.77 M
109.29 M
(13.56 M)
1.9 B
Current Valuation
914.35 K
(123.64 M)
2.05 B
3.5 B
9.69 B
8.44 B
697.6 M
90.02 M
13.18 B
Operating Margin
N/A
0.0122
0.0464
0.51
0.15
-0.14
0.037
-0.22
0.16
Price To Book
N/A
0.4
4.77
0.82
2.18
10.09
0.99
2.94
2.8
Retained Earnings
N/A
(146.94 M)
1000 K
N/A
4.65 B
(456.85 M)
380.62 M
(346.37 M)
4.25 B
Current Asset
N/A
457.65 M
N/A
N/A
1.95 B
N/A
159.83 M
675 M
6.32 B
Five Year Return
N/A
N/A
N/A
N/A
2.73
N/A
4.1
N/A
3.92
Beta
-2.82
1.07
N/A
0.86
0.73
1.1
0.26
-0.64
1.09
Number Of Employees
6
1.22 K
3.15 K
N/A
12 K
923
2.19 K
310
55.1 K
Shares Outstanding
380.98 K
63.39 M
86.13 M
58.39 M
65.16 M
166.99 M
10.64 M
3.99 M
372.52 M
Cash Flow From Operations
(31.75 K)
25.72 M
422 M
185.53 M
1.06 B
108.22 M
80.85 M
559 K
554.7 M
Annual Yield
N/A
N/A
0.0365
0.0346
0.0241
N/A
0.0313
N/A
0.0477
Total Debt
2.22 M
22.95 M
499 M
1.78 B
2.4 B
23.32 M
371.68 M
631 K
4.67 B
Return On Equity
N/A
0.0444
0.27
0.1
0.19
-0.12
0.12
-1.63
0.22
Book Value Per Share
-0.009
5.02
3.68
22.41
60.68
5.44
30.31
-1.46
10.0
Return On Asset
N/A
0.0037
0.11
0.0364
0.0792
-0.0546
0.0411
-0.3
0.0539
Number Of Shares Shorted
N/A
54.64 K
9.84 M
53.54 K
1 M
4.53 M
182.89 K
3.72 K
22.63 M
Current Liabilities
N/A
76.74 M
N/A
N/A
742 M
N/A
99.3 M
670 M
7.09 B
Total Asset
24.78 K
468.69 M
1.89 B
3.14 B
7.64 B
1.2 B
981.66 M
31.16 M
19.27 B
Debt To Equity
N/A
0.11
N/A
N/A
0.74
0.021
1.08
0.003
1.33
Short Ratio
N/A
0.26
16.25
1.88
2.04
9.01
7.24
0.86
3.05
Target Price
N/A
12.0
18.33
21.8
159.67
59.69
N/A
7.94
33.27
Last Dividend Paid
N/A
N/A
0.64
0.6
3.14
N/A
N/A
N/A
1.3
Shares Owned By Institutions
N/A
4.4
86.34
0.8
88.91
73.08
57.54
19.3
99.59
Market Capitalization
380.98 K
133.76 M
1.51 B
1.01 B
8.65 B
8.78 B
448.43 M
114.43 M
10.32 B
Price To Earning
N/A
15.85
N/A
N/A
18.78
N/A
11.33
1.75
13.69
Price To Earnings To Growth
N/A
N/A
0.52
N/A
1.71
-0.92
N/A
N/A
148.92
Price To Sales
0.52
0.42
0.55
2.58
1.15
13.87
0.2
3.21
1.1
Net Income
(31.75 K)
14.27 M
110 M
47.21 M
643 M
(133.81 M)
50.46 M
(15.03 M)
1.1 B
Earnings Per Share
-0.004
0.26
0.78
2.53
10.26
-0.59
3.48
-1.8
2.12
Shares Owned By Insiders
N/A
19.13
6.76
84.24
0.79
32.57
17.26
27.39
0.41
Revenue
N/A
363.72 M
2.76 B
360.59 M
8.16 B
569.95 M
2.24 B
27.11 M
10.89 B
Working Capital
N/A
199.29 M
(130 M)
41.57 M
1.63 B
246.95 M
25.48 M
(9.35 M)
619.5 M
Cash And Equivalents
30.87 K
259.91 M
N/A
N/A
322 M
284.54 M
134.83 M
33.68 M
2.55 B
Cash Per Share
0.04
3.82
N/A
N/A
4.91
1.81
9.29
0.95
4.55
Gross Profit
N/A
141.44 M
639 M
N/A
1.49 B
158.18 M
616.45 M
1.62 B
2.13 B
Day Typical Price
0.096
2.09
16.4
18.31
132.83
52.53
31.72
20.16
27.49
Accumulation Distribution
N/A
3346.4
126246.0
186.0
5304.97
23248.66
11901.17
0.0534
33325.0
Market Facilitation Index
N/A
0.0
0.0
0.0
0.0
0.0
0.0
1.11
N/A
Daily Balance Of Power
0.0
(0.12)
(1.06)
(0.76)
0.3607
0.219
0.632
(0.18)
(0.61)
Period Momentum Indicator
N/A
(0.01)
(1.18)
(0.26)
0.79
0.23
2.13
(0.20)
(0.17)
Rate Of Daily Change
1.0
1.0
0.93
0.99
1.01
1.0
1.07
0.99
0.99
Day Median Price
0.096
2.09
16.43
18.34
132.5
52.41
31.33
20.25
27.47
Price Action Indicator
N/A
0.005
(0.70)
(0.23)
1.41
0.49
2.25
(0.35)
(0.03)
Coefficient Of Variation
(539.08)
5887.52
2481.78
(4,548)
14820.62
414.31
4178.16
826.01
(1,288)
Mean Deviation
3.76
3.16
2.09
1.33
0.9898
1.63
1.56
3.1
1.12
Jensen Alpha
(1.75)
0.0596
0.1233
(0.05)
0.0059
0.5671
0.0493
0.5555
(0.14)
Total Risk Alpha
(1.75)
0.0628
0.1253
(0.05)
0.0066
0.5685
0.0507
0.5591
(0.14)
Sortino Ratio
N/A
0.0135
0.0465
N/A
0.004
0.3253
0.0252
0.1565
N/A
Downside Variance
N/A
20.0
7.07
N/A
1.95
3.04
3.88
12.64
N/A
Standard Deviation
9.41
4.12
3.3
1.78
2.24
2.39
2.47
4.67
1.69
Kurtosis
28.61
0.6518
9.84
1.24
36.69
7.19
13.48
4.12
5.73
Potential Upside
N/A
6.28
4.76
2.38
1.41
4.27
2.96
9.36
2.63
Treynor Ratio
(0.45)
(0.11)
0.2178
(0.55)
0.0034
1.06
0.0965
(0.68)
(0.26)
Maximum Drawdown
62.0
22.51
26.02
9.37
21.14
15.85
17.88
28.89
9.27
Variance
88.6
16.96
10.89
3.16
5.01
5.71
6.09
21.85
2.85
Market Risk Adjusted Performance
(0.44)
(0.1)
0.2278
(0.54)
0.0134
1.07
0.1065
(0.67)
(0.25)
Risk Adjusted Performance
(0.14)
0.0217
0.04
(0.01)
0.0118
0.201
0.026
0.1057
(0.06)
Skewness
(4.96)
(0.25)
1.6
(0.32)
4.99
1.73
2.63
1.29
(1.32)
Semi Deviation
N/A
4.05
2.59
N/A
1.37
1.2
1.92
3.04
N/A
Information Ratio
(0.19)
0.0147
0.0374
(0.03)
0.0025
0.2374
0.0201
0.119
(0.08)
Value At Risk
(12.73)
(6.57)
(2.80)
(2.96)
(1.80)
(2.90)
(3.20)
(4.95)
(2.21)
Expected Short fall
N/A
(3.44)
(2.43)
N/A
(1.10)
(1.90)
(1.58)
(3.94)
N/A
Downside Deviation
N/A
4.47
2.66
N/A
1.4
1.74
1.97
3.55
N/A
Semi Variance
N/A
16.4
6.73
N/A
1.88
1.44
3.7
9.23
N/A

Shanrong Biotechnology Competition Performance Charts

Five steps to successful analysis of Shanrong Biotechnology Competition

Shanrong Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Shanrong Biotechnology in relation to its competition. Shanrong Biotechnology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Shanrong Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Shanrong Biotechnology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Shanrong Biotechnology, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Shanrong Biotechnology position

In addition to having Shanrong Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Convertibles Funds Thematic Idea Now

Convertibles Funds
Convertibles Funds Theme
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Shanrong Pink Sheet Analysis

When running Shanrong Biotechnology's price analysis, check to measure Shanrong Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanrong Biotechnology is operating at the current time. Most of Shanrong Biotechnology's value examination focuses on studying past and present price action to predict the probability of Shanrong Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanrong Biotechnology's price. Additionally, you may evaluate how the addition of Shanrong Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY